Despite market concerns like emerging competition and low-entry barriers in the oncology treatment market, Genomic Health (GHDX) reported robust third-quarter earnings. It has strong growth potential in the international market, which is quickly becoming an important part of Genomic Health's growth story. I believe the underpenetrated market with thin competition should help Genomic Health continue its double-digit growth trajectory. With the NICE recommendation firmly in its pocket, Genomic Health should increase UK test volumes and prove its case successfully to other European countries, to incorporate the Oncotype DX Breast test. Additionally, seeing the growing unmet clinical need in prostate cancer, I believe Oncotype DX Prostate will also be a long-term growth driver for Genomic Health. With the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|